Skip to content
All Sections
Subscribe Now
82°F
Wednesday, August 21st 2024
e-Edition
Home Page
Close Menu
News
News
Crime and Public Safety
Investigative Reporting
Politics
Health
Environment
Business
Best Reviews
Housing
Jobs
Local News
Local News
Long Beach
Los Angeles
Los Angeles County
Sports
Sports
High School Sports
Chargers
Rams
Lakers
Clippers
Dodgers
Angels
College Sports
UCLA Sports
USC Sports
Long Beach State sports
Kings
Ducks
Olympics
Boxing/MMA
Soccer
Horse Racing
Things To Do
Things To Do
Restaurants Food and Drink
Movies
Music + Concerts
Theater
TV and Streaming
Home + Garden
Travel
Amusement Parks
Comics
Puzzles
Events
Obituaries
Obituaries
News Obituaries
Place an Obituary
Opinion
Opinion
Editorials
Opinion Columns
Commentary
Letters to the Editor
Editorial Board
Endorsements
The Grunion
The Grunion
News
Education
Sports
Things to Do
Opinion
E-Edition
Advertising
Contact Us
SCNG Premium
The T.E.A.
Subscribe
Press-Telegram Store
Log In
Logout
Close Menu
Get the latest news delivered daily!
Sign Up
Subscribe
Log In
Account Settings
Contact Us
Log Out
Spoof a user
Get the latest news delivered daily!
Sign Up
Subscribe
Log In
Search
Press Telegram
82°F
Wednesday, August 21st 2024
e-Edition
News
Local News
Sports
Things to Do
Obituaries
Opinion
The T.E.A.
Trending:
Pike Outlets shooting
Driver's licenses to go mobile
Long Beach's Olympic moment
Walker killed by dogs
Joe Jost's turns 100 ð
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by ImmunoGen, Inc.
< Previous
1
2
Next >
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 01, 2024
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 03, 2024
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
FDA Grants Priority Review of ImmunoGen’s Supplemental Biologics License Application for ELAHERE® (mirvetuximab soravtansine-gynx) in Platinum-Resistant Ovarian Cancer
December 05, 2023
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 01, 2023
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Jefferies London Healthcare Conference
November 02, 2023
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces European Medicines Agency Acceptance of Marketing Authorization Application for Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer
October 27, 2023
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 29, 2023
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 18, 2023
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Appoints Lauren White as Senior Vice President and Chief Financial Officer
September 18, 2023
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 05, 2023
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Collaboration with Takeda to Develop and Commercialize ELAHERE® in Japan
August 28, 2023
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 01, 2023
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Departure of Anna Berkenblit, Chief Medical Officer
July 31, 2023
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Reports Recent Progress and Second Quarter 2023 Financial Results
July 31, 2023
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Canaccord Genuity 43rd Annual Growth Conference
July 27, 2023
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Multi-Target License and Option Agreement with ImmunoBiochem to Develop Next-Generation Antibody-Drug Conjugates
July 24, 2023
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 03, 2023
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 01, 2023
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Jefferies Healthcare Conference
May 24, 2023
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
May 09, 2023
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Results from the Phase 3 MIRASOL Trial Selected as Late-Breaking Presentation for ASCO 2023 Annual Meeting
May 09, 2023
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Proposed Public Offering of Common Stock
May 03, 2023
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 01, 2023
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Reports Recent Progress and First Quarter 2023 Financial Results
April 28, 2023
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Appoints Isabel Kalofonos as Senior Vice President and Chief Commercial Officer
April 24, 2023
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Non-Dilutive Term Loan Financing for Up to $175 Million with Pharmakon Advisors
April 06, 2023
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 03, 2023
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Presents Final Overall Survival and Additional Efficacy Data from the SORAYA Trial at SGO Annual Meeting
March 25, 2023
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 01, 2023
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Reports Recent Progress and 2022 Financial Results
March 01, 2023
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Close